HGF inhibits BMP-induced osteoblastogenesis: Implications for the bone disease in multiple myeloma.

被引：0
|
作者：
Standal, Therese
Abildgaard, Niels
Fagerli, Unn-Merete
Stordal, Berit
Hjertner, Oyvind
Borset, Magne
Sundan, Anders
机构：
[1] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway
[2] Odense Univ Hosp, Dept Haematol, DK-5000 Odense, Denmark
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3451.3451
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3451
引用
收藏
页码：985A / 985A
页数：1
相关论文
共 50 条
  • [21] Effect of BMT on bone turnover in multiple myeloma.
    Clark, RE
    Ion, E
    Durham, B
    Fraser, W
    BONE MARROW TRANSPLANTATION, 1998, 21 : S200 - S200
  • [22] Allogeneic bone marrow transplantation for multiple myeloma.
    Kulkarni, S
    Powles, R
    Mehta, J
    Raje, N
    Singhal, S
    Horton, C
    Tait, D
    Treleaven, J
    BLOOD, 1998, 92 (10) : 352B - 352B
  • [23] An osteoprotegerin-like peptidomimetic (OP3-4) inhibits osteoclastic bone resorption and osteolytic bone disease in multiple myeloma.
    Heath, D. J.
    Vanderkerken, K.
    Cheng, X.
    Gallagher, O.
    Prideaux, M.
    Murali, R.
    Croucher, P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S82 - S82
  • [24] Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
    Croucher, PI
    Shipman, CM
    Perry, MJ
    Lippitt, J
    Asosingh, K
    van Beek, EJR
    Van Camp, B
    Russell, GG
    Dunstan, C
    Vanderkerken, K
    BLOOD, 2000, 96 (11) : 761A - 761A
  • [25] BMP-INDUCED BONE-FORMATION - DEPENDENCE ON GEOMETRY OF CELL SUBSTRATA
    KUBOKI, Y
    TSURUGA, E
    JOURNAL OF DENTAL RESEARCH, 1995, 74 (03) : 985 - 985
  • [26] INHIBITION OF BMP-INDUCED ECTOPIC BONE-FORMATION BY EXOGENOUS OSTEONECTIN
    TAKITA, H
    TSURUGA, E
    KOBAYASHI, D
    KUBOKI, Y
    JOURNAL OF DENTAL RESEARCH, 1995, 74 : 567 - 567
  • [27] Lineage tracking of mesenchymal and endothelial progenitors in BMP-induced bone formation
    Kolind, Mille
    Bobyn, Justin D.
    Matthews, Brya G.
    Mikulec, Kathy
    Aiken, Alastair
    Little, David G.
    Kalajzic, Ivo
    Schindeler, Aaron
    BONE, 2015, 81 : 53 - 59
  • [28] Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.
    Mohan, Meera
    Yarlagadda, Naveen Kumar
    Atwal, Dinesh
    Pandey, Yadav
    Roy, Arya
    Parikh, Richa
    Lopez, James
    Thanendrarajan, Sharmilan
    Schinke, Carolina D.
    Alapat, Daisy
    Van Rhee, Frits
    Kendrick, Samantha
    Zangari, Maurizio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] BMP-antagonist sclerostin is expressed in mineralized bone and blocks BMP-induced bone formation in vitro.
    van Bezooijen, RL
    Karperien, M
    Visser, A
    Hamersma, H
    Winkler, D
    Hayes, T
    Skonier, J
    Staehling-Hampton, K
    Latham, JA
    Papapoulos, SE
    Lowik, CWG
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S163 - S163
  • [30] Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
    Bernstein, Zachary S.
    Kim, E. Bridget
    Raje, Noopur
    CELLS, 2022, 11 (15)
12345